Melanoma Clinical Trial
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
Summary
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Eligibility Criteria
Inclusion criteria:
Patients must have melanoma that has spread beyond the original location and has not yet been treated.
Tissue from the spreading melanoma should have been tested to confirm it is melanoma.
Exclusion criteria:
Patients having hepatitis or HIV infection.
Taking corticosteroids.
Patients with the primary site being occular melanoma or patients with melanoma of the brain.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 20 Locations for this study
Los Angeles California, 90089, United States
San Francisco California, 94115, United States
Santa Monica California, 90404, United States
New Haven Connecticut, 06520, United States
Jacksonville Florida, 32209, United States
Miami Beach Florida, 33140, United States
Chicago Illinois, 60637, United States
Indianapolis Indiana, 46202, United States
Lutherville-Timonium Maryland, 21093, United States
New York New York, 10016, United States
Toledo Ohio, 43614, United States
Pittsburgh Pennsylvania, 15213, United States
Waratah New South Wales, 2298, Australia
Westmead New South Wales, 2145, Australia
Douglas Queensland, 4814, Australia
South Brisbane Queensland, 4101, Australia
Woolloongabba Queensland, 4102, Australia
Hobart Tasmania, 7000, Australia
East Melbourne Victoria, 3002, Australia
Nedlands Western Australia, 6009, Australia
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.